Two curcumin analogs inhibited the function and protein expression of breast cancer resistance protein : in vitro and in vivo studies

1. Two curcumin analogs, (1E,6E)-1,7-bis(3,5-diethyl-4-hydroxyphenyl)hepta-1,6-diene-3,5- dione (N17) and its prodrug ((1E,6E)-3,5-dioxohepta-1,6-diene-1,7-diyl)bis(2,6-diethyl-4,1- phenylene)bis(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate) (N17'), were evaluated as breast cancer resistance protein (BCRP) inhibitors.2. MDCKII-BCRP and MDCKII-WT were used to evaluate the modulation effects of N17 and N17' on BCRP and to explore the relevant mechanism. Sprague-Dawley rats were orally administered rosuvastatin (ROS), a probe substrate of BCRP, without and with N17' (100 mg/kg) to investigate the effect of N17' on ROS pharmacokinetics.3. In cell studies, N17 and N17' were substrates of BCRP, and they decreased the activity and protein expression of BCRP. In rat study, N17' increased the systemic exposure of ROS by 218% (p = 0.058).4. N17 and N17' are potential BCRP inhibitors and will be promising candidates for overcoming the BCRP-mediated multidrug resistance.

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:53

Enthalten in:

Xenobiotica; the fate of foreign compounds in biological systems - 53(2023), 5 vom: 02. Mai, Seite 454-464

Sprache:

Englisch

Beteiligte Personen:

Yu, Chung-Ping [VerfasserIn]
Wang, Yi-Ru [VerfasserIn]
Hou, Yu-Chi [VerfasserIn]
Hsieh, Min-Tsang [VerfasserIn]
Li, Pei-Ying [VerfasserIn]
Kuo, Sheng-Chu [VerfasserIn]
Lin, Shiuan-Pey [VerfasserIn]

Links:

Volltext

Themen:

ATP-binding cassette transporters
Breast cancer resistance protein
Curcumin analogs
Journal Article
Multidrug resistance
Rosuvastatin

Anmerkungen:

Date Revised 05.10.2023

published: Print-Electronic

Citation Status Publisher

doi:

10.1080/00498254.2023.2260886

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM362253412